// App-Quantinova.ai

P281 : Combined clinical and biological response (concomitant CRP and faecal calprotectin reductions) in induction and maintenance from the phase 3 ustekinumab Crohn’s disease studies

Researchers

Presenter

  • J -F Colombel

Principal Investigators

  • C Gasink

  • A Oortwijn

  • R van Kruchten

  • S Sloan

  • V Laliman

  • P Rutgeerts

  • S Ghosh

  • W Sandborn

  • B Feagan

  • B Sands

Medical Centers

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Janssen Scientific Affairs, Horsham, PA

  • Janssen Biologics, Leiden, Netherlands

  • Amaris International Consultancy, Toronto, Canada

  • University Hospital Gasthuisberg, Leuven, Belgium

  • University of Birmingham, Birmingham, United Kingdom

  • University of California, San Diego, La Jolla, CA

  • University of Western Ontario, Robarts Research Institute, London, ON, Canada

Locations

  • United States

  • Netherlands

  • Canada

  • Belgium

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • N/A

Biomarkers

  • C reactive protein

Drug/Treatment

  • Ustekinumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved